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Chemo irradiation therapyAbstract Rectal cancer is associated with a high risk of metastases and local recurrence; local
recurrence rates after surgical treatment being up to 32% (1). Local recurrence is directly related
to incomplete tumor resection (2, 3) and also related to the circumferential safety of resection (4,
5). An accurate local staging at the time of initial diagnosis is therefore very important.
Aim: The aim of this study is to use MRI in comparing the morphologic features of rectal cancer
before and after 6 weeks of chemo irradiation treatment and to correlate the post treatment MRI
appearances with the histological findings in resected tumors.
Material and methods: 68 patients with histopathologically proven rectal adenocarcinoma received
standardized 5-week chemo radiation therapy and subjected to MRI before and after treatment for
clinical staging. A correlation between pathological response and MRI findings was done.
Result: Sixty-eight patients with adenocarcinoma rectal cancer were included in the study. Preop-
erative MRI examination was performed. All patients subsequently underwent operation. The
mean time lag between the MRI study and operation was 16.8 days.
After preoperative chemo-radiotherapy, MRI findings showed that, there is a significant shift
toward downstaging. 16/59 (23.5%) patients achieved down-staging from clinical stage III (before
therapy) to stage II after therapy (P = 0.001) by achieving both tumor (T) downsizing and lymph
node downstaging. MR images obtained after radiation therapy with concomitant chemotherapy
have (100%) sensitivity, (78.7%) specificity, (100%) NPV in the differentiation of T1–2/T3–4
tumors with MRI, accuracy 80.9% with agreement 70.58% and 100% accuracy for node staging.
Conclusion: High resolution pre treatment MRI of the rectum has a high predictive value of treat-
ment outcome either for neoadjuvant treatment or surgery.
ª 2014 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/3.0/).
2 N.M. Elmashad et al.1. Introduction
Rectal cancer is associated with a high risk of metastases and
local recurrence; local recurrence rates after surgical treatment
being up to 32%.1 Local recurrence is directly related to
incomplete tumor resection 2,3 and also related to the circum-
ferential safety of resection.4,5 An accurate local staging at the
time of initial diagnosis is therefore very important. Tumor
depth of invasion staging, especially local staging (referred to
as T assessment), determines the treatment strategy. This
includes operation planning and the use of neoadjuvant ther-
apy.1 The total mesorectal excision, gives the best chance for
tumor-free circumferential resection margin, and this will
reduce the local recurrence rate.4 Preoperative chemoradiation
therapy has become the standard adjunctive preoperative
treatment of patients especially in patients where there is a
high likelihood of not achieving free surgical margin.6 MRI
has been shown to be highly accurate for local staging. As it
was less operator dependent, it enabled evaluation of anal infil-
tration as well as the depth of extramural invasion. It could
also be used to predict the circumferential resection margin.7
The tumor-free total mesorectal excision reduces the frequency
of pathologically involved margin of resection by tumor. This
benefit should lead to reduced rates of local tumor recurrence
and lower patient morbidity.8
2. Materials and methods
This is a prospective study that includes 68 patients with
biopsy-proven stage II or III rectal adenocarcinoma who
received standardized 5-week chemo radiation therapy over a






Symptoms Bleeding per rectum 51
Alternation of bowel habits 1
Signs Bleeding per touch 37
Mass detected clinically 13
Painful per touch 2
Distance from anal verge 65 cm 23
>5 cm 29
Operation Type Low anterior resection 11
abdomino-perineal Resection + colostomy 41
Margin Both margins are free 48




MRI morphology Eccentric wall thickening 19
Circumferential thickening 19
Polypoid growth 14tions for chemo radiation therapy were biopsy-proven locally
advanced rectal cancer. In this regard, a locally advanced rec-
tal cancer patient in our study was selected on the basis of
either tumor fixation by digital rectal examination or clinical
staging MRI findings of a high likelihood of circumferential
resection margin involvement and hence possibility of inade-
quate immediate resection.
Of note, tumors were classified clinically as rectal if the lower
limit was within 12 cm from the anal verge at sigmoidoscopy
 Informed consent was obtained from all patients after
full explanation of the technique of MRI which is
non invasive, without any risk approved till now.
 Privacy of all patients’ data is guaranteed.
Inclusion criteria: T3, T4 N0–3 adenocarcinoma rectal
cancer patients.
Exclusion criteria: Early T1–2 and/or distant metastatic
rectal adenocarcinoma.
2.1. Pre treatment evaluation
2.1.1. Clinical
Evaluation started with a complete history and accurate clini-
cal examination including digital rectal examination and per-
formance status (PS) of all patients according to ECOG PS
scoring.
2.1.2. Laboratory
Base line and before surgery complete blood count, liver and
renal function tests, electrolytes, tumor marker Carcino-
embryonic antigen (CEA) and CA19.9 level were performed.omitant radio chemotherapy and patient characteristics.
esponse Chi-square
able disease (SD) Partial response (PR) Total
% N % N % v2 P-value
20.59 6 8.82 20 29.41 0.639 0.424
55.88 10 14.71 48 70.59
75.00 14 20.59 65 95.59 2.651 2.651
1.47 2 2.94 3 4.41
54.41 13 19.12 50 73.53 4.145 0.126
19.12 1 1.47 14 20.59
2.94 2 2.94 4 5.88
33.82 8 11.76 31 45.59 0.164 0.686
42.65 8 11.76 37 54.41
16.18 16 23.53 27 39.71 37.702 0.001**
60.29 0 0.00 41 60.29
70.59 14 20.59 62 91.18 0.327 0.567
5.88 2 2.94 6 8.82
0.00 1 1.47 1 1.47 3.430 0.180
60.29 13 19.12 54 79.41
16.18 2 2.94 13 19.12
27.94 8 11.76 27 39.71 1.775 0.412
27.94 6 8.82 25 36.76
20.59 2 2.94 16 23.53
Table 2 Rectal tumor (T) down staging after induction radio-
chemotherapy by MRI.
T pre MRI staging T post MRI staging
T1 T2 T3 T4 Total
T2 N 2 12 0 0 14
% 2.94 17.65 0.00 0.00 20.59
T3 N 0 34 3 2 39
% 0.00 50.00 4.41 2.94 57.35
T4 N 0 0 10 5 15
% 0.00 0.00 14.71 7.35 22.06
Total N 2 46 13 7 68
% ‘ 67.65 19.12 10.29 100.00
Wilcoxon signed ranks test Z 6.351
P-value 0.001***
Table 3 MRI lymph node (N) down staging after induction
radio-chemotherapy.
MRI node staging MRI node staging
pre chemoradiotherapy Post chemoradiotherapy
cNo cN1 cN2 Total
cNo N 9 0 0 9
% 13.24 0.00 0.00 13.24
cN1 N 16 2 0 18
% 23.53 2.94 0.00 26.47
cN2 N 0 10 31 41
% 0.00 14.71 45.59 60.29
Total N 25 12 31 68
% 36.76 17.65 45.59 100.00
Wilcoxon signed ranks test Z 5.099
P-value 0.001**
cN = clinical radiological node.
Role of MRI in rectal carcinoma after chemo-radiation therapy with pathological correlation 32.1.3. Radiologically
 Abdomino-pelvic ultrasound of all patients.
 Chest X-ray and/or computed tomography (CT) if needed
to exclude pulmonary metastasis of all patients.
 Abdominal CT with contrast to exclude liver metastasis.
 Pelvic Magnetic Resonance Imaging (MRI): All cases
underwent MRI examination in the Radio diagnosis
Department (Tanta University) using a machine (GE signa
1.5 Tesla) with abdominal surface coil. All patients were
positioned in the supine position. The following sequences
are used, axial, sagittal and coronal T2WI. Axial cuts with
fat saturated fast spin-echo T2WI and TIWI were obtained.
Also axial, sagittal and coronal T1WI were taken immedi-
ately after a manual intravenous injection of 0.1 mg of
Gd-DTPA/kg of body weight (Magnevist: Schering Berlin,
Germany). Patients were asked to do breath-holding tech-
niques to the extent tolerable.
2.1.4. Image analysis
MRI images were evaluated on a work station. Tumors were
classified into two groups according to their anatomic location:
low rectal tumors were diagnosed when less than 5 cm from the
anal verge, upper and middle rectal tumors were diagnosed
when more than 5 cm from the anal verge.
MR signal intensity of rectal mucosa and submucosa
appear (inner hyperintense) followed by muscularis propria
(appearing as hypointense intermediate layer). Then perirectal
fat tissue (appearing as hyperintense layer), the mesorectal fas-
cia appear as thin low intensity structure which envelops the
mesorectum and the surrounding perirectal fat tissue. Also
the extramesorectal lymph nodes were detected. The depth of
the tumor invasion, the mesorectal infiltration, and number
of enlarged lymph nodes were assessed. Mesorectal fascia
was clearly delineated.
Each rectal tumor was staged according to the MRI find-
ings and was later correlated with the operative and patholog-
ical findings. The depth of mural invasion by the tumor was
staged according to the TNM staging system.9
We characterized T1 tumors by an infiltration of the sub-
mucosal layer and a sparing of the muscularis propria. When
the tumor invades muscularis propria we accepted the tumor
as T2. T2 lesions were differentiated from T3 lesions by iden-
tification of a smooth outer tumor border within the rectal wall
with no invasion into the fat surrounding the rectum. T3
lesions had irregular outer borders and invaded the fat sur-
rounding the rectum either by a plaque, mass, or cordlike sig-
nal intensity that projected into the perirectal fat. The presence
of spiculation within the fat alone was not sufficient evidence
of an extramural invasion. In T4 lesions, fat planes between
the rectal carcinoma and surrounding organs disappeared.
Mesorectal fascia involvement and the invasion into adjacent
organs were also noted as indicators of T4 tumors. Mesorectal
and extramesorectal lymph nodes with irregular margins and/
or a short axis greater than 5 mm were accepted as metastatic.9
2.1.4. Treatment
Treatment is carried out in three Clinical Oncology centers:
Tanta, Alexandria and Assiut. Radiation therapy for rectal
cancer patients using Linear accelerator Photon 15 MeVVarian Medical Systems, Palo Alto, CA (United States) and
Siemens Primus (German) Serial No. 3301; Radiotherapy dose
consisted of a total of 5040 cGy delivered in 28 fractions of
180 cGy, five times a week, to the pelvis with individually
shaped portals and the use of a four-field box technique. Con-
comitant chemotherapy used oral capecitabine (Xeloda)
825 mg/m2 tablets twice daily throughout radiotherapy with-
out interruption. Clinical and radiological restaging was per-
formed 6 weeks after completion of preoperative treatment.
Surgical resection either with anterior resection or abdomi-
no-perineal resection was performed 6–8 weeks after comple-
tion of the chemo radiation therapy according to the
principles of total mesorectal excision.
Patients were monitored for toxicity as radiation dermatitis,
diarrhea and if needed were scored according to the National
Cancer Institute Common Terminology Criteria for adverse
Events (version 3.0).8
2.2. Ethical approval
Ethical and record linkage approvals were obtained from the
Human Research Ethics Committee at the University of Tanta
and the Confidentiality of Health Information Committee of
Tanta and from Human Researches Ethics Committee at Assi-
ut University.
4 N.M. Elmashad et al.3. Result
Sixty-eight adenocarcinoma rectal cancer patients were
included in the study (M:F = 48:20). The commonest clinicalTable 4 Rectal cancer downstaging after induction radio-
chemotherapy by MRI.
MRI stage before therapy MRI stage after therapy
Stage II Stage III Total
Stage II N 9 0 9
% 13.24 0.00 13.24
Stage III N 16 43 59
% 23.53 63.24 86.76
Total N 25 43 68
% 36.76 63.24 100.00
Wilcoxon signed ranks test Z 4.000
P-value 0.001**
Table 5 Correlation between histo-pathological and post chemo-ra
















PPV= positive predictive value; NPV= negative predictive value.
Table 6 Correlation between histo-pathological and post chemo-ra
















ypN= pathological node.presentation was per-rectal bleeding (95.6%, n= 65). Preoper-
ative MRI examination was performed. No treatment inter-
ruption occurred as no major toxicity occurred. All patients
subsequently underwent operation. The mean time lag between
the MRI study and operation was 16.8 days. 27 (39.71%)
patients achieved a statistically significant partial response to
concomitant radio chemotherapy and underwent low anterior
resection and 41 (60.29%) patients abdomino-perineal resec-
tion + colostomy (P value 0.001**) (Table 1).
3.1. MRI down staging after induction radio-chemotherapy
After preoperative chemo-radiotherapy, there is a significant
shift toward downstaging. 16/59 (23.5%) patients achieved
down-staging by tumor (T) downsizing (Table 2) and lymph
node (N) downsizing (Table 3) and from clinical stage III
(before therapy) to stage II after therapy (P = 0.001)**
(Table 4) by achieving both.diotherapy MRI findings for rectal tumor (T) staging.
herapy MRI staging (T staging)
T2 T3 T4 Total
0 0 0 2
0.00 0.00 0.00 100.00
46 13 0 59
77.97 22.03 0.00 100.00
0 0 7 7
0.00 0.00 100.00 100.00
46 13 7 68
67.65 19.12 10.29 100.00
Specificity PPV NPV Accuracy
78.7% 35% 100% 80.9%
diotherapy MRI findings for LN (N) staging.










Specificity PPV NPV Accuracy
100% 100% 100% 100%
Figure 1 Axial T2 MR cuts showing soft tissue mass of
intermediate to high T2 signal intensity (S1) on the antero-lateral
aspect of the lower rectum 9 O’clock (arrow) with loss of the
muscularis propria and early infiltration of the adjacent mesorec-
tal fat represent early T3.
Figure 3 Coronal T2 MRI showing right lower third rectal mass
about 2 cm from levator ani puborectalis insertion (arrow).
Role of MRI in rectal carcinoma after chemo-radiation therapy with pathological correlation 5The accuracy of pre-operative MRI versus pathological
staging after either low anterior resection or abdomino-peri-
neal resection:
Using Wilcoxon signed ranks test, there is a significantly
strong correlation between histopathological and post MR
images obtained after radiation therapy with concomitant
chemotherapy in the differentiation of T2/T3 tumors
(z= 4.472; P = 0.001**).
When compared with pathological findings after surgical
manipulation, MRI achieved 100% sensitivity, 78.7% specific-
ity, 100% NPV, 80.9% accuracy with an agreement of 70.58%
for rectal tumor (Table 5). MRI showed 100% accuracy for
detection of node staging (Table 6).Figure 2 Axial T2 MR cuts showing soft tissue mass of
intermediate to high T2 signal intensity (S1) on the antero-lateral
aspect of lower rectum 6–9 O’clock (arrow) with loss of the
muscularis propria and early infiltration of the adjacent mesorec-
tal fat represent early T3.
Figure 4 Axial MR sequence showing T1 soft tissue mass in the
posterior right lateral rectal wall (arrow) with clear invasion into
mesorectal fat.3.1.1. Case number 1
Female patient 60 years old presented by bleeding per rectum
2 months, Pre chemo-irradiation MRI (Figs. 1–3) show ante-
ro-lateral aspect of lower rectum 6–9 O’clock rectal adenocar-
cinoma with loss of the muscularis propria and early
infiltration of the adjacent mesorectal fat. Post therapy MRI
shows regression course of rectal adenocarcinoma with down
staging of early T3 fi T1 (Figs. 4 and 5) which correlates with
post operative low anterior resection of pathological finding of
the complete response (Fig. 6) with no evidence of adenocarci-
noma (100% accuracy).
3.1.2. Case number 2
A male patient 38 years old presented with bleeding per rectum
for 6 months. With alternation of bowel habits rectal
adenocarcinoma is proved by punch biopsy before starting
Figure 5 Coronal T2 MRI showing right lower third rectal mass
1 cm from levator ani puborectalis insertion (arrow).
Figure 6 Histo pathological examination showing chronic non
specific chemoradiotherapy induced proctitis showing transmural
lymphoplasmacytic inflammatory infiltrate, glandular architec-
tural atypia but with preserved mucin production (arrow). No
granuloma & no malignancy include H&E X100 (100%
agreement).
Figure 7 Pre-therapeutic sagittal T2 MRI sequence show
circumferential wall thickening mainly at the ano-rectal junction,
narrowing the lumen.
Figure 8 Post therapeutic sagittal T2 MRI examination of the
ano-rectal junction showing slight regressive course of the previ-
ously detected mass (arrow).
6 N.M. Elmashad et al.concurrent chemo-radiotherapy. Pre chemo-irradiation MRI
shows circumferential wall thickening mainly at the ano-rectal
junction and narrowing of the lumen T3 (Fig. 7).
Post chemo-irradiation MRI shows stationary course of T3
rectal adenocarcinoma (Figs. 8 and 9) which correlates with
post operative abdomino-perineal resection pathological find-
ing (Fig. 10) of no response with evidence of adenocarcinoma
(100% accuracy).
4. Discussion
There are different modalities for diagnosis of rectal tumors
including barium enema, and either colonoscopy or sigmoidos-
copy. However these endoluminal techniques do not provide
significant information about the extraluminal spread of the
tumor needed for preoperative planning. Now several imagingmethods have been used to assess the accurate spread of the
tumor, such as endorectal ultrasound (EUS), computed
tomography (CT) and MRI.10
Many studies have reported that MRI shows excellent over-
all accuracies in the diagnosis of mesorectal fascia spread and
invasion into adjacent organs (88100% and 100%, respec-
tively).11–13 However this high accuracy rate was not achieved
either by EUS or multi detector CT.14 Differentiation between
T3 from T2 lesions is very important mainly for preoperative
therapy, and the most important criterion is the invasion into
perirectal fat. Early criteria for an assignment of pT3 in MRI
are the absence of hypointensity of the muscle layer seen
between the edge of the tumor and the extramural soft tissue.15
Infiltration of tumor to the perirectal fat is the best indica-
tor of T3 tumor on MRI images. However it is difficult to
Figure 9 Axial T2 MRI sequence examination revealing also the
slight regression of the circumferential thickening seen at recto
anal junction (arrow).
Figure 10 Histo pathological examination after chemo radio-
therapy showing residual of malignancy (arrow) H&E X100 with
100% post therapy MRI agreement.
Role of MRI in rectal carcinoma after chemo-radiation therapy with pathological correlation 7differentiate spiculation seen in the perirectal fat caused only
by fibrosis from that spiculation caused by fibrosis containing
tumor cells.16
The mesorectal fascia that represents the CRM, and hence
invasion into the CRM has a high recurrence rate.17 In our
work, neoadjuvant chemo-radiotherapy leads to down staging
of the tumor in terms of its T and N stages as we investigated
the MR accuracy obtained after radiation therapy with con-
comitant chemotherapy for the prediction of down staging of
tumors confined to the rectal wall T3–4/T1–2 by using histo-
pathologic findings (ypT3/T1–2 lesions) as the reference stan-
dard in patients with cancerous rectum. After preoperative
chemo radiotherapy there is a significant shift toward earlier
TNM stages with significant down-staging from stage III before
therapy to stage II after therapy (P value = 0.001). MR images
obtained after concomitant chemo-irradiation have 100% sen-
sitivity, 78.7% specificity, 100% NPV for the prediction oftumor downsizing to a ypT0–2 lesion with accuracy 80.9%.
This result agrees with that of Williamson18 and Chari.19
In our studyMRI shows 100%accuracy in the differentiation
of N0/N1–2 tumors (z= 4.472; P= 0.001) with sensitivity
100%, specificity 100% (Table 6) with agreement 70.58%. This
concords with Beets-Tan and colleagues who investigated 76
patients and foundpreoperativeMRI to be accurate in the assess-
ment of CRM. The agreement is 100% in T4 tumors, and 97%
and 93% for both readers in tumors with a histologically deter-
mined tumor-free CRM >10 mm.10,11 The low accuracy of
MR imaging in these studies could be explained by the low spatial
resolution that was used with early MRI techniques in 2001. But
even with higher spatial resolutions in the new generation of
phased-array coils, the accuracy for T staging was not as high
as expected, with values varying between 65% and 86%.11,20–22
One exception to the above was the study done by Brown
and colleagues6 who reported 100% accuracy and complete
agreement between two readers on the diagnosis of tumor
stage with MR imaging results. The most difficult staging with
MR imaging occurs in the differentiation of T2-stage and bor-
derline T3-stage lesions. This is mainly due to the over-staging
of the tumor. Over-staging is caused mainly by desmoplastic
reactions.6,11,22 In our work there is strong correlation between
histopathological and post MRI tumor staging in the differen-
tiation of T2/T3 (Z= 472; P = 0.001) and also in the differen-
tiation of N1/N2 (Z= 472; P = 0.001). This is in concordance
with Minsky and others in 1995 as MRI and histology for T
staging have ranged from 66% to 94%. The main difficulty
with MRI has been the differentiation between two stages T2
and T3. However, the definitive treatment being the same for
both these stages, this means the differentiation does not play
a huge impact on patient outcome.23
On the other hand, in a study Bissett and his colleague
reported good agreement between preoperative MRI and
histopathology as regards tumor invasion detection through
the mesorectal fascia with an high accuracy of 95%.24 The
exact staging is very important because the number of met-
astatic nodes has been shown to affect the prognosis of the
disease.25 Lymph node involvement in the vicinity of the
mesorectal fascia is associated with a higher risk of local
recurrence,2 and therefore the accuracy in the detection of
lymph nodes is essential for accurate treatment. Patients
with metastatic lymph nodes outside the mesorectal fascia
need extended lymph node resection with removal of the
internal iliac lymph nodes.11 This group of lymph node is
not removed when TME is done.
Nodal staging by MRI usually depends on the size crite-
ria. Typically a lymph node is considered malignant when
the short axis of the lymph node measures over 0.5 cm.26
Also the lymph node features such as ill defined edges, dis-
similarity of signal enhancement within the node increase
the accuracy of MRI.27 This can explain achieving 100%
accuracy in our study. The disappointing accuracy seen in
MRI imaging in staging rectal cancer is due to both overstag-
ing and under-staging. Over staging, in the assessment of
invasion into the rectal wall, occurs because after radiother-
apy the responding tumors are replaced by fibrosis, inflam-
matory and vascular proliferation.28 Promising strategies of
imaging using lymph node specific paramagnetic nano parti-
cles have been reported to increase the accuracy in the detec-
tion of micro metastasis.29
8 N.M. Elmashad et al.5. Conclusion
MRI plays an important role in the multimodality imaging
used in the treatment of patients with cancerous rectum. Accu-
rate preoperative staging is very important for making effec-
tive therapeutic decisions. MRI accurately delineates the
extent of primary tumor. Regarding the depth of tumor inva-
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